AN2 Therapeutics
ANTX
35 hedge funds and large institutions have $10.5M invested in AN2 Therapeutics in 2025 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 7 increasing their positions, 11 reducing their positions, and 3 closing their positions.
20% more capital invested
Capital invested by funds: $8.78M → $10.5M (+$1.73M)
2.83% more ownership
Funds ownership: 27.45% → 30.29% (+2.8%)
3% less funds holding
Funds holding: 36 → 35 (-1)
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
36% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Squarepoint
New York
|
+$62K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$50.4K |
| 3 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$22.2K |
| 4 |
AA
ACT Advisors
Asheville,
North Carolina
|
+$15.1K |
| 5 |
Morgan Stanley
New York
|
+$14.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$48K |
| 2 |
LCM
Landscape Capital Management
Englewood,
New Jersey
|
-$44.5K |
| 3 |
IWC
Integrated Wealth Concepts
Waltham,
Massachusetts
|
-$26.5K |
| 4 |
Two Sigma Investments
New York
|
-$17.2K |
| 5 |
Renaissance Technologies
New York
|
-$15.2K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SSA
26
Schonfeld Strategic Advisors
New York
| $18.1K | -$3.24K | -2,834 | -17% |
|
|
AA
27
ACT Advisors
Asheville,
North Carolina
| $16.8K | +$15.1K | +13,199 | New |
|
28
Federated Hermes
Pittsburgh,
Pennsylvania
| $15.1K | -$406 | -355 | -3% |
|
29
Qube Research & Technologies (QRT)
London,
United Kingdom
| $12.9K | – | – | – |
|
|
HWP
30
Highline Wealth Partners
Sherman Oaks,
California
| $6.35K | – | – | – |
|
|
TRCT
31
Tower Research Capital (TRC)
New York
| $2.7K | -$3.64K | -3,185 | -60% |
|
32
Fidelity Investments
Boston,
Massachusetts
| $1.27K | +$1.14K | +1,000 | New |
|
33
BNP Paribas Financial Markets
Paris,
France
| $385 | -$10 | -9 | -3% |
|
34
Osaic Holdings
Scottsdale,
Arizona
| $384 | – | – | – |
|
|
SS
35
SBI Securities
Tokyo,
Japan
| $254 | – | – | – |
|
|
36
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$48K | -45,320 | Closed |
|
|
IWC
37
Integrated Wealth Concepts
Waltham,
Massachusetts
| – | -$26.5K | -25,000 | Closed |
|
|
HF
38
HRT Financial
New York
| – | -$13K | -12,678 | Closed |
|
ANTX Hedge Fund Activity: Q3 2025 in Review
35 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in AN2 Therapeutics (ANTX) for Q3 2025, worth a combined $10.5M — up 20% from $8.78M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of ANTX and 2 opened new positions — a net loss of 1 holder — while 11 trimmed existing stakes and 7 added.
The largest buyer was Squarepoint, adding an estimated $62K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $48K sold.
- 35 institutional investors held AN2 Therapeutics (ANTX) as of Q3 2025, down from 36 in Q2 2025.
- Funds reported $10.5M of AN2 Therapeutics stock for Q3 2025, up 20% quarter-over-quarter.
- 2 funds opened new AN2 Therapeutics positions in Q3 2025 and 3 closed out, a net change of -1 holder.
- The largest AN2 Therapeutics buyer in Q3 2025 was Squarepoint, an estimated $62K added.
- The largest AN2 Therapeutics seller in Q3 2025 was Susquehanna International Group, an estimated $48K sold.
Based on aggregated 13F filings for Q3 2025.